Pfizer Celebrex Sales Reps Will Discuss Alternate Therapy, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer will include FDA’s recommendation that prescribers consider alternative therapy in its promotion to doctors. The company has also agreed to suspend direct-to-consumer advertising for the COX-2 inhibitor following release of trial data showing an increased cardiovascular risk for patients on the drug.
You may also be interested in...
Pfizer Sees Celebrex Script Growth After Bextra Withdrawal
Script data indicates patients are switching from Bextra to Celebrex, Pfizer says. In the last three weeks, Celebrex has led the NSAID market in new prescription growth.
Pfizer Sees Celebrex Script Growth After Bextra Withdrawal
Script data indicates patients are switching from Bextra to Celebrex, Pfizer says. In the last three weeks, Celebrex has led the NSAID market in new prescription growth.
COX-2 Sales Reps Remain "Extraordinarily Busy" At Pfizer
Celebrex and Bextra had strong fourth quarter sales despite Merck's withdrawal of Vioxx, CEO McKinnell says. Pfizer will hold off on deciding whether to restructure its COX-2 inhibitor team until after an FDA advisory committee review next month.